University of Oxford and AstraZeneca sign deal to produce COVID-19 vaccine
A new agreement between the University of Oxford and AstraZeneca will allow the former's COVID-19 vaccine candidate to be manufactured and distributed.
List view / Grid view
News
Sartorius closes acquisition of selected assets of Danaher Life Sciences
Sartorius has announced the completed acquisition of some life science businesses of Danaher for a total of $825 million.
UK vaccine clinical trial outsourcing expansion continues
An outsourcing company has announced that Phase II, III and IV clinical trials of vaccines will continue at a growing number of sites, assessing the safety of each in light of COVID-19.
WHO launches Access to COVID-19 Tools Accelerator
The World Health Organization (WHO) has launched its Access to COVID-19 Tools Accelerator, a collaboration to progress the development of coronavirus vaccines and therapeutics.
Utilising CRISPR could reduce contamination in recombinant-protein drugs
Researchers have used CRISPR-Cas to edit the genes of contaminating proteins in mammalian cells used to produce recombinant-protein drugs, which could reduce costs and strengthen quality.
Gilead announces primary endpoints met in Phase III remdesivir trial
Gilead has said that topline results for clinical recovery have been demonstrated in a Phase III trial of remdesivir, tested in COVID-19 patients.
WHO calls for pharma to rapidly distribute malaria prevention and treatment tools
In light of the COVID-19 pandemic, WHO has asked the pharmaceutical supply chain to swiftly distribute nets and antimalarial medicines in sub-Saharan Africa.
International regulators pledge support to combat COVID-19
The EMA has announced its support for the International Coalition of Medicines Regulatory Authorities' call for global collaboration in the fight against COVID-19.
Microbial compound in new fluconazole formulation used to combat Candida albicans
Researchers have used a specific chemical signal released from a major bacterial pathogen to improve the activity of fluconazole against Candida biofilms.
FDA sends two warnings to companies selling unapproved CBD products
Two companies selling unapproved cannabidiol (CBD) products including for the treatment of opioid addiction, have been handed warning letters from the FDA.
Supportive therapy better than novel treatments for COVID-19, say scientists
Instead of using new or repurposed treatment for COVID-19, doctors should focus on traditional critical care principles for patients, scientists have said.
Researchers design first new polio vaccine in 50 years
A polio vaccine designed to be incapable of evolving the ability to cause disease in humans has shown promise in a Phase I clinical trial.
NIAID strategic plan for COVID-19 focuses on developing assays, therapeutics and vaccines
The US National Institute of Allergy and Infectious Diseases (NIAID) has revealed its research priorities relating to COVID-19, including supporting the development and testing of potential therapeutics and vaccines.
MERS vaccine shows promise in clinical trial, say researchers
A clinical trial to study a MERS vaccine has demonstrated success, say researchers, suggesting their technology could be repurposed to halt the spread of COVID-19.
£14m funding to support rapid COVID-19 vaccine manufacturing scale up
The UK Bioindustry Association industry-led vaccine manufacturing group has welcomed a £14 million investment to support COVID-19 vaccine manufacturing.
